Sandoz is a global leader in generic pharmaceuticals and biosimilars and a division of the Novartis Group. Our purpose is Making Access Happen by pioneering novel approaches to help people around the world access high-quality medicine and support the the UK's growing healthcare needs.
Our global portfolio comprises approximately 1,000 molecules, covering all major therapeutic areas. Our broad offering translates into substantial and ongoing savings for patients and payors, which help to ensure the sustainability of healthcare systems in the face of significant budgetary pressures, while also freeing up funding for innovative medicines.
Our products reach approximately 500 million patients worldwide.1 Sandoz is committed to increasing patient access to high-quality biosimilars in the UK. We annually supply approximately 112 million packs of medicines to UK NHS patients.2 Our broad portfolio is spearheaded by our global leadership position in both biosimilars, the “cutting edge” of innovative off-patent medicines, and generic antibiotics, the foundation of global healthcare. We also run a broad range of targeted corporate responsibility programs to increase access to medicine, medical information and appropriate medical training for healthcare professionals.